Diamyd Medical
17.18
SEK
+0.47 %
DMYD B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
+0.47%
+4.5%
0%
+28.59%
+4.12%
+106.99%
+15.54%
-6.1%
+469.5%
Diamyd Medical is a diabetes company. The company develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trial.
Read moreMarket cap
1.79B SEK
Turnover
3.12M SEK
Revenue
130K
EBIT %
-112,746.15 %
P/E
-
Dividend yield-%
-
Financial calendar
9/4
2025
Interim report Q2'25
25/6
2025
Interim report Q3'25
8/10
2025
Annual report '25
ShowingAll content types
Diamyd Medical AB: Delårsrapport 1 24/25
Diamyd Medical AB: Sydkorea beviljar Diamyd Medical precisionsmedicinskt patent för behandling med insulin-antigen vid autoimmun diabetes
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools